Success Metrics

Clinical Success Rate
53.8%

Based on 7 completed trials

Completion Rate
54%(7/13)
Active Trials
0(0%)
Results Posted
71%(5 trials)
Terminated
6(35%)

Phase Distribution

Ph phase_3
2
12%
Ph phase_4
10
59%
Ph not_applicable
2
12%
Ph phase_1
1
6%

Phase Distribution

1

Early Stage

0

Mid Stage

12

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
1(6.7%)
Phase 3Large-scale testing
2(13.3%)
Phase 4Post-market surveillance
10(66.7%)
N/ANon-phased studies
2(13.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

46.7%

7 of 15 finished

Non-Completion Rate

53.3%

8 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Completed(7)
Terminated(8)
Other(2)

Detailed Status

Completed7
Terminated6
unknown2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
53.8%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (6.7%)
Phase 32 (13.3%)
Phase 410 (66.7%)
N/A2 (13.3%)

Trials by Status

terminated635%
unknown212%
withdrawn212%
completed741%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT05490381Phase 1

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

Withdrawn
NCT03631771Phase 4

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

Withdrawn
NCT03671603

Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium

Completed
NCT05065073Phase 4

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

Unknown
NCT00348608Phase 3

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Terminated
NCT00335335Phase 3

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Terminated
NCT01188486Not Applicable

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Terminated
NCT01146639Not Applicable

DynaCT in Preoperative Imaging Before Insertion of Stentgraft

Completed
NCT01326364

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Terminated
NCT01848899Phase 4

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Completed
NCT01475097Phase 4

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

Completed
NCT01376089Phase 4

Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis

Completed
NCT01580046Phase 4

Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction

Unknown
NCT01402219Phase 4

Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients

Terminated
NCT01075217Phase 4

Isovue in Peripheral Digital Subtraction Angiography (DSA)

Completed
NCT00782639Phase 4

Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients

Terminated
NCT00827788Phase 4

Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17